Hennion & Walsh Asset Management Inc. Acquires 60,720 Shares of Intellia Therapeutics, Inc. $NTLA

Hennion & Walsh Asset Management Inc. boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 38.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 220,523 shares of the company’s stock after buying an additional 60,720 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.16% of Intellia Therapeutics worth $3,731,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. AQR Capital Management LLC increased its position in shares of Intellia Therapeutics by 154.1% during the first quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock worth $646,000 after acquiring an additional 55,118 shares in the last quarter. Woodline Partners LP bought a new stake in Intellia Therapeutics in the 1st quarter valued at $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Intellia Therapeutics by 8.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after purchasing an additional 38,521 shares during the period. Creative Planning boosted its stake in Intellia Therapeutics by 12.9% in the 2nd quarter. Creative Planning now owns 33,102 shares of the company’s stock worth $310,000 after purchasing an additional 3,795 shares during the period. Finally, Cetera Investment Advisers increased its holdings in Intellia Therapeutics by 47.4% during the 2nd quarter. Cetera Investment Advisers now owns 33,532 shares of the company’s stock worth $315,000 after purchasing an additional 10,785 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Up 0.7%

NASDAQ:NTLA opened at $12.02 on Tuesday. Intellia Therapeutics, Inc. has a twelve month low of $7.95 and a twelve month high of $28.25. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -3.58 and a beta of 1.81. The stock’s 50 day moving average price is $13.61 and its two-hundred day moving average price is $13.48.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, meeting the consensus estimate of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The company had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. During the same quarter in the prior year, the firm posted ($0.98) EPS. The firm’s revenue for the quarter was down 46.4% compared to the same quarter last year. As a group, analysts anticipate that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on NTLA shares. Wolfe Research downgraded Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price target on the stock. in a research note on Wednesday, July 15th. Wall Street Zen downgraded Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Citigroup reissued a “market outperform” rating on shares of Intellia Therapeutics in a research report on Monday, June 15th. New Street Research set a $25.00 target price on Intellia Therapeutics in a research note on Monday, June 15th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $30.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $20.85.

Insider Buying and Selling at Intellia Therapeutics

In other news, EVP Edward J. Dulac III sold 4,677 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the transaction, the executive vice president directly owned 156,286 shares in the company, valued at $2,813,148. The trade was a 2.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the sale, the chief accounting officer directly owned 66,886 shares in the company, valued at approximately $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 3.50% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.